"Khavinson peptides" — more formally peptide bioregulators — are a family of very short peptides, often just two to four amino acids long, developed since the 1970s by the Russian scientist Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology. The central claim is unusual and ambitious: that each tiny peptide is a tissue-specific "bioregulator" which travels to one particular organ and helps normalise how its genes are expressed — slowing the changes of aging in that tissue specifically.
It is a genuinely interesting idea with a large body of supporting work. It is also a body of work with a real problem, which this page will not hide.
The core idea
The theory grew out of an observation Khavinson's group reported: a peptide preparation made from pineal-gland extract stimulated the growth of pineal tissue in a dish, but not other tissues — and preparations from other organs stimulated their own respective tissues1. From this came the concept of tissue specificity: a cartilage peptide for cartilage, a prostate peptide for prostate, a pineal peptide for the pineal gland, and so on.
Two generations of products followed:
- Cytamins — the original preparations, complex peptide extracts purified from animal tissues.
- Cytogens (or "cytomaxes") — later, *synthetic* short peptides (di-, tri-, and tetrapeptides) meant to reproduce the active core. Epitalon (AEDG), Vilon (KE), and others belong here.
In lab studies from the group, these short peptides shift aging-related markers in cultured cells — for example increasing a proliferation marker (Ki-67) and reducing markers of cell senescence and breakdown2. The proposed mechanism is that the peptides enter cells and even the nucleus, interacting with DNA and nudging gene expression back toward a "younger" pattern.
The family (the ones you'll see sold)
| Peptide | Marketed target tissue | Notes |
|---|---|---|
| Epitalon (Epithalon) | pineal gland · aging · telomerase | The flagship and most-studied — see our epitalon guide |
| Cartalax | cartilage · joints | Marketed for joint / connective tissue |
| Prostamax | prostate | Marketed for prostate / urinary health |
| Testagen | reproductive / testicular tissue | Marketed for male reproductive support |
| Ovagen | ovarian / reproductive tissue | Marketed for female reproductive support |
| Livagen | liver | Marketed for liver support |
| Vilon (KE) · Vesugen · Pinealon | immune · vascular · brain | Other named cytogens in the same system |
The honest evidence problem
Here is what the sales pages leave out:
- It is almost all one group. The great majority of published studies on these peptides come from Khavinson's own institute and its collaborators. A large output from a single originating group, with little independent replication, is a classic reason for scientific caution.
- Much of it is cells, animals, and Russian-language journals. The mechanism and anti-aging findings are largely in vitro and in rodents; a lot is published in Russian or in specialist bulletins, and rigorous, independently-run human clinical trials are scarce. (For the ones that are in Russian, this isn't a translation barrier we've skipped — Russian biomedical journals indexed in PubMed/MEDLINE supply an English abstract regardless of the article's language, and we've read those. The gap is independent replication, not access.)
- We specifically checked Cartalax, Prostamax, Testagen, Ovagen, and Livagen — and found no dedicated, on-topic published study for any of them. A literature search under their product names, their likely peptide codes, and their claimed target tissue turned up either nothing, or papers on an unrelated tissue that merely share the same short-peptide chemistry (a "cartalax" search, for instance, surfaced real Khavinson-group papers — but on kidney and thymus aging, not cartilage). We won't cite a kidney study as evidence for a cartilage product; that would be a mismatch, not a citation. Epitalon is the one member of this family with substantial, name-matched, tissue-specific published research — which is exactly why it is the only one with its own page on this site.
- The claims are extraordinary. Tissue-specific gene regulation and lifespan extension are big claims, and big claims need the strongest evidence — which, for most of these peptides, does not yet exist outside the originating group, and for several, does not yet clearly exist at all under a search of their own name.
None of this proves the peptides do nothing — an unpublished or untranslated effect could still be real. It means the confident "regenerates your [organ]" marketing runs well ahead of what independent, on-topic science has actually shown, and for most of the individually-named products, well ahead of what any published science shows at all.
Regulatory status
Khavinson peptides are sold as dietary supplements (cytamins / cytogens), not approved medicines. Western regulators such as the FDA have not evaluated or approved them for any medical use. This page explains the concept and the evidence honestly — not how to use them — and it takes no position on sourcing.
The short version
Khavinson peptide bioregulators are a family of very short, "tissue-specific" peptides from a Russian research program that claims they normalise gene expression and slow aging in a targeted organ — cartilage, prostate, liver, pineal gland, and more. The idea is interesting and the group's output is large, but the evidence is overwhelmingly from that single group, much of it in cells, animals, and Russian journals, with little independent replication or rigorous human trials — and for Cartalax, Prostamax, Testagen, Ovagen, and Livagen specifically, we found no dedicated, on-topic published study under any name we searched. They are supplements, not approved medicines. Our best-studied example, with substantial name-matched research, is epitalon. Educational overview only, not medical advice.